Psychedelics
Canada Invests Nearly $3 Million in Psilocybin-Assisted Psychotherapy Research
LOS ANGELES- The Government of Canada, through the Canadian Institutes of Health Research (CIHR), has committed nearly $3 million to fund three clinical trials investigating psilocybin-assisted psychotherapy as a treatment for various mental health and substance use disorders. Funded Clinical Trials: Psilocybin-Assisted Existential, Attachment, and Relational Therapy for Advanced Cancer Patients: Led by Dr. Sarah Hales at the University of Toronto, this trial focuses on alleviating end-of-life psychological distress in patients with advanced-stage cancer. Mechanisms Supporting Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder: Conducted by Dr. Leah Mayo at the University of Calgary, this study examines the safety and efficacy of psilocybin in treating alcohol use disorder. Psilocybin-Assisted Psychotherapy for Treatment-Resistant ...
Atai Life Sciences Reports Positive Results from BPL-003 Phase 2a Study
LOS ANGELES- Atai Life Sciences has announced favorable outcomes from a Phase 2a open-label study evaluating BPL-003, an intranasal formulation of 5-MeO-DMT benzoate, in patients with moderate to severe alcohol use disorder (AUD). The study involved 12 participants who received a single dose of BPL-003 in conjunction with relapse prevention cognitive behavioral therapy. The findings revealed significant and sustained reductions in alcohol consumption over a 12-week period. Notably, 50% of the participants maintained complete abstinence throughout the study duration. BPL-003 was well-tolerated, with only mild to moderate adverse events reported, and no serious or severe adverse events occurred. Most patients were ready for discharge approximately two hours post-administration. These results ...
Awakn Life Sciences Advances Therapeutics for Substance Use and Mental Health Disorders
LOS ANGELES- Awakn Life Sciences Corp. a biotechnology company, has reported progress in its research and development programs targeting Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD). AWKN-001: This investigational therapy combines intravenous ketamine with cognitive behavioral therapy (CBT) for severe AUD. Currently in a Phase 3 trial in the UK, co-funded by the UK's Medical Research Council and the National Institute for Health and Care Research, Awakn's financial commitment is capped at £800,000. The company aims for a Regulation 52b hybrid application in the UK, potentially granting up to 10 years of market exclusivity upon approval. AWKN-002: This program involves a proprietary oral thin film formulation of esketamine, ...
Rhode Island Proposes Psilocybin Legalization and State-Regulated Therapy Program Pending Federal Rescheduling
LOS ANGELES- In January 2025, Rhode Island lawmakers introduced House Bill 5186, aiming to legalize psilocybin possession and cultivation for personal use. The bill proposes that individuals be allowed to cultivate psilocybin within their residences for personal use. Additionally, contingent upon the U.S. Food and Drug Administration (FDA) rescheduling psilocybin and expanding its access program, the Rhode Island Department of Health would be mandated to establish rules and regulations for its cultivation, distribution, and medical prescription. This legislative effort reflects a growing trend in the United States to reevaluate the legal status of certain psychedelics, particularly in the context of their potential therapeutic benefits. The bill's progression will depend on ...
European Citizens Launch Initiative to Promote Psychedelic-Assisted Therapies
LOS ANGELES- A coalition of healthcare professionals, academics, and advocates has initiated the PsychedeliCare European Citizens' Initiative (ECI), aiming to enhance access to psychedelic-assisted therapies across the European Union. The campaign seeks to collect one million signatures from at least seven EU member states by January 2026, compelling the European Commission to consider legislative action. The initiative's objectives include establishing standardized guidelines for the safe use of psychedelics in therapeutic settings, increasing EU funding for research into psychedelic therapies, and adopting a unified stance on the legal classification of psychedelics at the international level. Proponents argue that these measures could address the stagnation in psychiatric treatment innovation and provide effective ...
Colorado Considers Psilocybin Prescription Legislation
LOS ANGELES- Colorado lawmakers have introduced House Bill 25-1063, a bipartisan proposal that would permit the prescription of crystalline polymorph psilocybin—a synthetic form of the psychedelic compound—contingent upon approval by the U.S. Food and Drug Administration (FDA). The bill, sponsored by Representatives Anthony Hartsook (R) and Kyle Brown (D), aims to provide healthcare providers with an additional treatment option for patients experiencing conditions such as post-traumatic stress disorder (PTSD) and treatment-resistant depression. Representative Hartsook, a combat veteran, emphasized the potential benefits for veterans, stating, "This bill is about a prescription-level medication that's a derivative... designed to treat veterans or anybody that has PTSD, a traumatic brain injury, depression that hasn't ...
Psilocybin Therapy Shows Promise for Pandemic-Induced Depression in Healthcare Workers
LOS ANGELES- Recent studies indicate that psilocybin-assisted psychotherapy may alleviate depression among healthcare professionals affected by the COVID-19 pandemic. A randomized clinical trial conducted by the University of Washington involved 30 frontline clinicians experiencing moderate to severe depression. Participants received either a 25 mg dose of psilocybin or a placebo, alongside psychotherapy sessions. The psilocybin group exhibited a significant reduction in depression symptoms compared to the placebo group, with improvements sustained over six months. This research suggests that psilocybin, combined with psychotherapy, could be a viable treatment for depression in healthcare workers resulting from pandemic-related stress. However, experts emphasize the necessity for larger-scale studies to confirm these findings and to assess ...
Compass Pathways Advances Psilocybin Research in the UK
LOS ANGELES- Compass Pathways, a biotechnology company specializing in mental health innovations, has commenced the UK segment of its global Phase 3 clinical trial evaluating COMP360 psilocybin therapy for treatment-resistant depression (TRD). This initiative follows approval from the UK's Medicines and Healthcare products Regulatory Agency. The Phase 3 program comprises two pivotal trials: COMP 005 and COMP 006. The COMP 006 trial, now active in the UK, will assess three dosage levels of COMP360 (25mg, 10mg, and 1mg) across multiple research sites, including the newly established Centre for Mental Health Research and Innovation in London. The Centre for Mental Health Research and Innovation, officially opened on November 15, 2023, is ...
Ottawa’s Psilocybin Retailers Maintain Operations Amid National Enforcement Actions
LOS ANGELES- In Ottawa, several storefronts openly selling psilocybin, the psychoactive compound in magic mushrooms, continue to operate with minimal interference from local law enforcement. This contrasts with actions in other Canadian municipalities, where authorities have conducted raids and shut down similar establishments. The Golden Teacher, located at the corner of Rideau and Dalhousie streets, has been in operation since December 2021, offering products such as dried mushrooms, gummies, chocolates, and microdose capsules containing psilocybin. Another retailer, Shroomyz, situated on Preston Street, commenced operations in May 2022. Despite the illegality of psilocybin sales under the Controlled Drugs and Substances Act, these businesses have remained largely unimpeded. In August 2023, Ottawa ...
Kaya Holdings Unveils Psilocybin Therapy Series at Sacred Mushroom Center
LOS ANGELES- Kaya Holdings, Inc. a in wellness and mental health solutions, has announced an inaugural open house event for its psilocybin treatment center, The Sacred Mushroom™. The event will take place on Friday, December 27, 2024, from 5:00 PM to 8:00 PM, at its facility in Portland, Oregon. The open house offers attendees an exclusive opportunity to explore the center's private treatment rooms, indoor garden, and therapeutic activities, which include artistic expression, music, movement, and mindfulness practices. Guests will also receive detailed information on the center's services and the upcoming series of psilocybin microdosing sessions. The Sacred Mushroom™ is launching a new initiative, “Community, Culture, and a Touch of ...
FDA Restricts Psychoactive Mushroom in Edibles
LOS ANGELES- The U.S. Food and Drug Administration (FDA) has issued a warning regarding the use of Amanita muscaria (fly agaric) mushrooms and their psychoactive compounds—muscimol, ibotenic acid, and muscarine—in food products. The FDA has determined that these substances are not approved for use in conventional foods and may pose health risks to consumers. This action follows reports of adverse health events, including illnesses and fatalities, linked to the consumption of edibles containing these compounds. Notably, products marketed as "psychedelic edibles" or "legal psychedelics," which often resemble conventional snacks, have been associated with serious health issues such as seizures, confusion, and abnormal heart rates. The FDA's assessment concluded that Amanita ...
Psychedelics Show Promise in Alleviating End-of-Life Psychological Distress
LOS ANGELES- Recent studies indicate that psychedelics, particularly psilocybin, may help reduce depression, anxiety, and existential distress in patients with terminal illnesses. A systematic review published in Psychopharmacology analyzed data from various studies and found that psychedelic-assisted therapy led to significant reductions in these symptoms among patients facing life-threatening conditions. Another review in Current Oncology Reports highlighted psilocybin's potential benefits in palliative care, noting its favorable safety profile and sustained anxiolytic and antidepressant effects. However, the review also emphasized the need for more extensive research to address limitations such as selection bias and short follow-up periods. Despite these promising findings, challenges remain in integrating psychedelic therapies into standard end-of-life care. ...
Psychedelic Drugs Market Poised for Growth: From $0.7B in 2022 to $2.6B by 2032
The global psychedelic drugs market is projected to expand from $0.7 billion in 2022 to $2.6 billion by 2032, reflecting a compound annual growth rate (CAGR) of 13.4%.According to Allied Market Research This growth is driven by increasing acceptance of alternative mental health treatments and substantial investments in psychedelic research and development. Market Drivers Rising Prevalence of Mental Health Disorders: The increasing incidence of conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD) has led to a demand for innovative therapeutic options, including psychedelic-assisted therapies. Advancements in Clinical Research: Ongoing studies are exploring the efficacy of substances like psilocybin and ketamine in treating various mental health conditions, contributing to ...
HYTN Innovations Secures UK Import Permits and Initial Order from 4C Labs
LOS ANGELES- HYTN Innovations Inc., a pharmaceutical company specializing in psychoactive and psychotropic compounds, including cannabis and psilocybin, has received initial orders and import permits from the United Kingdom's 4C Labs. This development enables HYTN to commence exporting cannabis-based pharmaceuticals to the UK under recently established agreements. The first shipment, produced in compliance with Good Manufacturing Practices (GMP) standards, signifies HYTN's commitment to delivering high-quality cannabis products to international markets. CEO Elliot McKerr remarked, "This milestone underscores the strength of our collaboration and signals the shift from a domestic to international cannabis company." To facilitate this export, HYTN completed registration with the UK's National Drugs Control System (NDS), authorizing transactions ...
Cybin Reports 79% Remission in MDD with CYB003, Prepares for Phase 3 Trials
LOS ANGELES- Cybin Inc., has announced promising results from its Phase 2 study of CYB003, a proprietary deuterated psilocybin analog developed for the treatment of major depressive disorder (MDD). The study demonstrated that 79% of patients achieved remission from depression symptoms six weeks after receiving two 12mg doses of CYB003. The trial also reported rapid and significant improvements in depression symptoms following a single dose of CYB003. Patients experienced an average reduction of 13.75 points on the Montgomery–Åsberg Depression Rating Scale (MADRS) at the three-week mark, a statistically significant difference from the placebo group. The administration of a second dose at six weeks resulted in an additional 5.8-point improvement on ...
Psilocybin Shows Potential for OCD and Tourette’s Treatment, Study Finds
LOS ANGELES- A new study published in Molecular Psychiatry has identified psilocybin, a psychedelic compound, as a promising candidate for the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome. Conducted by researchers at the Hadassah-Hebrew University Medical Center, the study highlights the long-lasting therapeutic effects of psilocybin in preclinical trials using animal models. Led by Professor Bernard Lerer, the research focused on genetically modified mice that exhibit behaviors akin to OCD-like symptoms—such as excessive grooming—and tics, which are characteristic of Tourette's syndrome. The study evaluated the impact of a single dose of psilocybin, a psychedelic mushroom extract, or a placebo, with researchers observing the results over a three-week period. The ...
Massachusetts Voters Reject Medical Use of Psychedelics in Close Ballot Measure
LOS ANGELES- Massachusetts voters have rejected a proposed measure to legalize the medical use of certain psychedelics, with 57% voting against and 43% in favor. The initiative sought to permit the use of psilocybin, psilocin, dimethyltryptamine (DMT), ibogaine, and mescaline for therapeutic treatment in patients aged 21 and older. It would have allowed patients to grow these substances at home and undergo treatment at licensed centers under the guidance of certified facilitators. The measure's supporters argued that psychedelic therapies could significantly benefit patients struggling with mental health issues such as depression, PTSD, and cancer-related anxiety. They also suggested the initiative could create a pathway to tax revenue from a regulated ...
Cybin Secures Patent for CYB005 Program in Push for New CNS Disorder Treatments
LOS ANGELES- Cybin Inc., a neuropsychiatric biopharmaceutical company, announced that it has secured a U.S. patent (No. 12,122,741) covering the composition of matter for key molecules in its CYB005 program. This patent represents a strategic step for Cybin in developing non-hallucinogenic treatment options targeting central nervous system (CNS) disorders. The company’s CYB005 compounds, derived from the phenethylamine class, are being investigated for their ability to address mental health conditions by engaging serotonin 5-HT1A and 5-HT2C receptors—well-known targets in CNS therapeutic research. In recent years, interest in non-psychedelic treatments within the psychedelics field has risen, as companies seek compounds that can yield therapeutic benefits without hallucinogenic effects. Doug Drysdale, Cybin’s CEO, ...
Psyence Biomed Progresses in Psilocybin Development for Alcohol Use Disorder
LOS ANGELES- Psyence Biomed, a biopharmaceutical company focused on psychedelic therapeutics, has provided an update on its development of high-purity psilocybin in collaboration with PsyLabs. The company is working towards producing Active Pharmaceutical Ingredients (APIs) certified under the European Union’s Good Manufacturing Practices (GMP). This certification is critical for advancing psilocybin as a treatment for Alcohol Use Disorder (AUD). The progress update highlights PsyLabs' commitment to supplying high-purity, pharmaceutical-grade psilocybin for future clinical trials. Psyence Biomed’s partnership with PsyLabs also includes a pending acquisition of an equity stake, which will further integrate the two companies. This collaboration is expected to streamline the production and distribution of nature-derived psilocybin, facilitating its ...
Psychedelics Market Sees Growth Amid Regulatory and Investment Shifts
LOS ANGELES- The psychedelics market in the U.S. is witnessing rapid expansion, driven by both regulatory advancements and increasing investor interest. The sector, valued at approximately $603.1 million in 2024, is projected to grow at a compound annual growth rate (CAGR) of 7%, with expectations of reaching $1.18 billion by 2034. This growth stems largely from the rising interest in psychedelics as treatments for mental health conditions such as post-traumatic stress disorder (PTSD), treatment-resistant depression, and addiction. Key regulatory developments have bolstered the industry. In 2024, the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designations for psilocybin and MDMA, signaling accelerated development and testing of these drugs for ...
Massachusetts Voters Divided Over Psychedelics Legalization Ahead of 2024 Ballot
LOS ANGELES- Massachusetts voters are set to decide on Question 4 in the upcoming November 5 ballot, which proposes the legalization and regulation of certain psychedelic substances for therapeutic and personal use. If approved, Massachusetts would join Oregon and Colorado as states that have enacted similar measures. Recent polling indicates a closely contested issue: 42% of voters support the initiative, while 44% oppose it. The proposed law would permit adults aged 21 and over to possess, cultivate, and use specific natural psychedelics, including psilocybin, psilocyn, mescaline, DMT, and ibogaine, under regulated conditions. Advocates highlight potential mental health benefits, citing research that suggests these substances can aid in treating conditions like ...
New Jersey Senate Committee Advances Therapeutic Psilocybin Bill
LOS ANGELES- The New Jersey Senate Budget and Appropriations Committee has approved Senate Bill 2283, advancing legislation to legalize the therapeutic use of psilocybin for medical purposes. The bill, sponsored by Senate President Nick Scutari (D), comes after months of deliberation and amendments that shifted the focus from adult recreational use to strictly medical applications. The bill, if enacted, would allow individuals with qualifying medical conditions, as determined by a licensed health care professional, to use psilocybin under a regulated system. The New Jersey Department of Health would oversee the production and distribution process, granting licenses for five specific sectors: testing laboratories, manufacturers, facilitators, service centers, and psilocybin workers. The ...
Psyence Biomed Advances Clinical Trials in Psilocybin for Mental Health Treatments
LOS ANGELES- Psyence Biomedical Ltd. a life science biotechnology company focused on natural psychedelics for mental health, has issued updates on its progress in clinical research and corporate development. The company is leading efforts to develop natural psilocybin products for palliative care, with a focus on addressing psychological trauma and mental health challenges. Psyence is currently conducting a double-blind, placebo-controlled Phase IIb clinical trial in Australia, testing nature-derived psilocybin in three doses (25mg, 10mg, and 1mg) combined with psychotherapy. The trial aims to improve the quality of life for patients suffering from Adjustment Disorder, particularly those with life-limiting illnesses. The study’s primary endpoint is the change in the Hamilton Anxiety ...
Silo Pharma Advances Regulatory Path for PTSD Treatment SPC-15
LOS ANGELES- Silo Pharma, Inc. a developmental stage biopharmaceutical company, has submitted a proposal for FDA approval of its PTSD treatment, SPC-15, through the 505(b)(2) regulatory pathway. This pathway is designed to shorten clinical timelines and reduce development costs. The company recently completed a pre-Investigational New Drug (pre-IND) meeting with the FDA, receiving feedback to support opening an IND for first-in-human trials of SPC-15, an intranasal treatment for PTSD and stress-induced anxiety. CEO Eric Weisblum stated that the company now has a clear path to clinical development, with plans to bring SPC-15 to market following FDA approval. Silo is currently conducting pharmacokinetic and pharmacodynamic studies as part of its ongoing ...
FDA Consideration of Psilocybin Therapy Could Impact Millions of Depression Patients
LOS ANGELES- Recent research suggests that the active ingredient in psychedelic mushrooms, psilocybin, may offer significant benefits for individuals struggling with depression, pending approval from the U.S. Food and Drug Administration (FDA). With roughly one in 10 American adults experiencing depressive illness annually, the potential for psilocybin therapy to alleviate symptoms has garnered increasing attention. Psilocybin has shown promise in treating major depressive disorder, with studies suggesting that just two doses could provide relief for up to a year. Although the FDA has not yet approved psilocybin-assisted therapy, several breakthrough therapy designations have been granted for its use in treatment-resistant depression. This condition affects individuals who have not responded to ...